Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analytical challenges in mapping the subcellular metabolome and lipidome.

The Analyst·2026
Same author

Reshaping Ru polypyridyl photochemistry with choline-geranate (CAGE) ionic liquids.

Chemical communications (Cambridge, England)·2026
Same author

Targeting NAD Homeostasis: Compartmentalization, Quantification, and Modulation.

Metabolites·2026
Same author

Tunable soy protein isolate hydrogel for nanoparticles brain release.

Journal of materials science. Materials in medicine·2026
Same author

Cerebrospinal fluid CEFA composition is enriched in saturated fatty acids and it is altered in Alzheimer's disease.

Journal of lipid research·2026
Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026

Related Experiment Video

Updated: May 25, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
06:14

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Published on: May 8, 2018

Nanotechnology for neurodegenerative disorders.

Francesca Re1, Maria Gregori, Massimo Masserini

  • 1Department of Experimental Medicine, University of Milano-Bicocca, Monza, Italy. francesca.re1@unimib.it

Maturitas
|January 21, 2012
PubMed
Summary

Nanomaterials offer promising solutions for delivering drugs and imaging agents across the blood-brain barrier, crucial for treating neurodegenerative diseases. This review explores their therapeutic and diagnostic potential, alongside neuroprotection and regeneration strategies.

More Related Videos

Preparation of Neuronal Co-cultures with Single Cell Precision
09:06

Preparation of Neuronal Co-cultures with Single Cell Precision

Published on: May 20, 2014

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

Related Experiment Videos

Last Updated: May 25, 2026

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue
06:14

Novel Passive Clearing Methods for the Rapid Production of Optical Transparency in Whole CNS Tissue

Published on: May 8, 2018

Preparation of Neuronal Co-cultures with Single Cell Precision
09:06

Preparation of Neuronal Co-cultures with Single Cell Precision

Published on: May 20, 2014

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Neuroscience

Background:

  • Drug and imaging agent delivery to target sites, especially the brain, is a significant challenge in treating various disorders.
  • The blood-brain barrier (BBB) poses a major obstacle to effective pharmacological interventions for neurodegenerative diseases.
  • Engineered nanomaterials offer unique physicochemical properties and multi-functionalization capabilities to overcome biological barriers.

Purpose of the Study:

  • To review the current applications of nanomaterials for diagnosing and treating neurodegenerative disorders.
  • To explore the use of nanomaterials in neuroprotection and neuronal tissue regeneration.
  • To discuss the potential neurotoxicity of nanomaterials and future nanotechnological advancements.

Main Methods:

  • Literature review of current research on nanomaterials for neurodegenerative diseases.
  • Analysis of nanomaterial properties relevant to crossing the blood-brain barrier.
  • Evaluation of studies on therapeutic, diagnostic, neuroprotective, and regenerative applications of nanomaterials.

Main Results:

  • Nanomaterials show potential for enhanced drug delivery and diagnostic imaging across the BBB.
  • Multi-functionalized nanomaterials can be tailored for specific targeting and therapeutic effects.
  • Research indicates promise in using nanomaterials for neuroprotection and promoting neuronal regeneration.

Conclusions:

  • Nanomaterials represent a significant advancement in addressing the challenges of brain targeting for neurodegenerative diseases.
  • Further research into nanomaterial design and neurotoxicity is essential for clinical translation.
  • Future nanotechnological approaches hold promise for improved therapies and regenerative strategies for neurological disorders.